Is Teva (TEVA +1.06%) genuinely concerned about Biogen's (BIIB +0.94%) BG-12's safety, or is it more concerned about the oral MS drug's impact to its own Copaxone sales? Motley Fool health-care analyst David Williamson dives into the surprise plea to the FDA and what it means for investors.
